Skip to main content
. 2023 Nov 11;14:7301. doi: 10.1038/s41467-023-42900-4

Fig. 4. Tornado plot showing types of AEs in patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (safety population as of July 7, 2023).

Fig. 4

*Subjects who had a fatal AE recorded and died were not recorded as due unequivocally to disease under study. Pneumonitis; immune-related pneumonitis, urosepsis. Myelosuppression, respiratory failure. §No new immune-related deaths were observed. AE adverse event, CT chemotherapy, IO immuno-oncology agent, ir immune-related, SAE serious adverse event.